DUBLIN – The drug development graveyard that is Alzheimer's disease (AD) has claimed another victim, as Astrazeneca plc and Eli Lilly & Co. halted development of the beta secretase cleaving enzyme (BACE) inhibitor lanabecestat (AZD-3293; LY-3314814), after an independent data monitoring committee concluded that two phase III trials of the drug were unlikely to meet their primary endpoints.